Answers are grounded in this paper and cite their sources.
Campylobacter spp. have become the most important bacteria causing diarrhea in humans in many countries of the world (4). The most important species is Campylobacter jejuni, accounting for over 90% of the infections (4), with Campylobacter coli accounting for most of the remaining infections (6, 7). Macrolides are the drugs of choice for treatment of human infected withCampylobacter spp. Only limited prevalence of macrolide resistance has been detected for C. jejuni (1), especially that of human origin, while a higher prevalence has been found for C. coli (6, 7, 9, 10).Campylobacter spp. are considered zoonotic pathogens (1), and resistance among isolates in the animal reservoir could have implications for the treatment of infections in humans (8). The genetic background for macrolide resistance inCampylobacter spp. has not previously been identified. Some have reported indications of horizontal transfer of macrolide resistance between Campylobacter spp. (3), while others have not been able to transfer macrolide resistance (11).
No takes yet. Share an insight, caveat, or question.
Frank M. Aarestrup (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: